다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Current opinion in pulmonary medicine, v.22 no.3, 2016년, pp.196 - 202
Dy, Rajany (aDivision of Pulmonary, Critical Care, and Sleep Medicine, University at Buffalo, State University of New York bVeterans Affairs Western New York Healthcare System, Buffalo, New York, USA) , Sethi, Sanjay
PURPOSE OF REVIEW: Traditional culture methods have identified airway bacterial pathogens that cause acute exacerbations of chronic obstructive pulmonary disease (COPD), and contribute to airway inflammation and COPD progression. However, conventional microbiology is limited by low sensitivity and bias toward predetermined and predominant pathogens. Highly sensitive, unbiased microbiome techniques overcome these limitations. Here, we present recent lung microbiome data, specifically in the context of smoking, COPD, and exacerbations. RECENT FINDINGS: In contrast to the sterile lung environment found with conventional microbiology, microbiome techniques demonstrate a lower respiratory tract microbiome in health. Alterations in the lung microbiome with smoking and COPD have been clearly demonstrated by culture techniques, however, the findings in microbiome studies are limited and controversial. Increasing COPD disease severity is associated with a reduction in microbial diversity. Though microbial community structure does not change with exacerbation, there are notable changes in its composition. Antibiotic and corticosteroid treatment of acute exacerbations of COPD have significant but opposing effects on microbiome composition. SUMMARY: The composition of the lung microbiome changes with smoking, the severity of COPD, during acute exacerbations and with the use of steroids and/or antibiotics. Understanding the role of the microbiome in disease progression and development of exacerbations will lead to novel therapies.
Gill Science 2006 10.1126/science.1124234 312 1355
Proctor Cell Host Microbe 2011 10.1016/j.chom.2011.10.001 10 287
Morgan PLoS Comput Biol 2012 10.1371/journal.pcbi.1002808 8 e1002808
Huse PLoS One 2012 10.1371/journal.pone.0034242 7 e34242
Turnbaugh Nature 2007 10.1038/nature06244 449 804
Cox Hum Mol Genet 2013 10.1093/hmg/ddt398 22 R88
Chakravorty J Microbiol Methods 2007 10.1016/j.mimet.2007.02.005 69 330
Beck Transl Res 2012 10.1016/j.trsl.2012.02.005 160 258
Huang Am J Respir Crit Care Med 2013 10.1164/rccm.201303-0488WS 187 1382
Kiley Chest 2011 10.1378/chest.11-0774 140 497
Hilty PLoS One 2010 10.1371/journal.pone.0008578 5 e8578
Erb-Downward PLoS One 2011 10.1371/journal.pone.0016384 6 e16384
Charlson Am J Respir Crit Care Med 2011 10.1164/rccm.201104-0655OC 184 957
Soler Eur Respir J 1999 10.1183/09031936.99.14510159 14 1015
Sethi Am J Respir Crit Care Med 2006 10.1164/rccm.200509-1525OC 173 991
Sethi N Engl J Med 2008 10.1056/NEJMra0800353 359 2355
Morris Am J Respir Crit Care Med 2013 10.1164/rccm.201210-1913OC 187 1067
Pragman PLoS One 2012 10.1371/journal.pone.0047305 7 e47305
Sze Am J Respir Crit Care Med 2012 10.1164/rccm.201111-2075OC 185 1073
Galiana Eur Respir J 2014 10.1183/09031936.00191513 43 1787
Garcia-Nunez J Clin Microbiol 2014 10.1128/JCM.01967-14 52 4217
Millares Eur J Clin Microbiol Infect Dis 2014 10.1007/s10096-013-2044-0 33 1101
Desai Ann Am Thorac Soc 2014 10.1513/AnnalsATS.201310-350OC 11 303
Huang OMICS 2010 10.1089/omi.2009.0100 14 9
Huang J Clin Microbiol 2014 10.1128/JCM.00035-14 52 2813
Molyneaux Am J Respir Crit Care Med 2013 10.1164/rccm.201302-0341OC 188 1224
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.